EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Chemotherapy-induced peripheral neuropathy associated with docetaxel or nab-paclitaxel among patients with lung cancer: a prospective dual-center cohort study

Chemotherapie-induzierte periphere Neuropathie unter Docetaxel oder nab-Paclitaxel bei Patient:innen mit Lungenkrebs: prospektive Kohortenstudie an zwei Zentren

Yalan Liu, Yurong Li, Xin Li, Hui Zhang, Xinfu Liu, Peng Chen

Frontiers in Pharmacology · 11.06.2026 · 17

DOI: 10.3389/fphar.2026.1795686 ↗

Auf einen Blick

Bei 850 Patient:innen mit Lungenkrebs unterschied sich die CIPN je nach Taxan. Unter nab-Paclitaxel traten die Symptome ausgeprägter auf als unter Docetaxel.

Fragestellung

Unterscheidet sich die klinische Ausprägung einer chemotherapieinduzierten peripheren Neuropathie unter Docetaxel versus nab-Paclitaxel bei Lungenkrebs?

Methode

Prospektive Kohortenstudie an 2 Zentren in China von September 2024 bis August 2025; Bewertung mit EORTC QLQ-CIPN20, multivariable Regression und overlap propensity score weighting.

Ergebnisse

850 Teilnehmende; 385 erhielten Docetaxel, 465 nab-Paclitaxel. Docetaxel: geringeres CIPN-Risiko als nab-Paclitaxel (HR 0,65; 95 %-KI 0,54–0,86; P=0,015). Weniger sensorische Beschwerden (HR 0,61; 95 %-KI 0,49–0,89; P=0,001).

Schlussfolgerung der Autor:innen

Nach Angaben der Autor:innen war nab-Paclitaxel mit schwererer CIPN als Docetaxel assoziiert, unabhängig von klinischen Merkmalen. Taxanart, frühere Zyklen, Behandlungsphase und Pregabalin waren unabhängige Faktoren.

Kernaussagen

  • CIPN trat unter nab-Paclitaxel ausgeprägter auf als unter Docetaxel.
  • Docetaxel war mit geringerem CIPN-Risiko assoziiert (HR 0,65).
  • Sensorische Beschwerden waren unter Docetaxel seltener; motorische/autonome nicht signifikant.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.06.2026. Verfasst von Yalan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the distinct clinical manifestations of chemotherapy-induced peripheral neuropathy (CIPN) in patients with different types of lung cancer treated with docetaxel or nab-paclitaxel, as well as to evaluate the post-intervention symptom improvement following therapeutic management.

Methods

This prospective cohort study was conducted from September 2024 to August 2025 across two medical centers in China. Participants were lung cancer patients who had received treatment with either docetaxel or nab-paclitaxel. Chemotherapy-induced peripheral neuropathy (CIPN) was assessed using patient-reported outcomes from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN 20-item scale (EORTC QLQ-CIPN20). Multivariable regression models were adjusted for patient baseline characteristics, tumor status, and medication-related features. Evaluations were performed using overlap propensity score weighting. Data analysis was carried out from September 2025 to December 2025.

Results

Among the 850 participants, the mean (SD) age was 63.2 (10.5) years, with 385 patients (45.3%) receiving docetaxel and 465 patients (54.7%) receiving nab-paclitaxel. The docetaxel group primarily reported motor symptoms (e.g., leg weakness: 92 patients [34.2%]) and autonomic symptoms (e.g., blurred vision: 108 patients [40.1%]). In contrast, the nab-paclitaxel group predominantly reported sensory symptoms, such as numbness in the hands and feet (68 patients [25.3%]). The onset of patient-reported motor symptoms occurred earlier than sensory abnormalities, with median times of 2.3 weeks (95% CI, 1.3–5.4) in the docetaxel group and 0.8 weeks (95% CI, 0.6–1.2) in the nab-paclitaxel group. After adjustment using overlap propensity score weighting, patients in the docetaxel group had a lower risk of reported CIPN compared to those in the nab-paclitaxel group (HR, 0.65 [95% CI, 0.54–0.86]; P = 0.015). Patients treated with docetaxel reported fewer sensory discomforts compared to those receiving nab-paclitaxel (HR, 0.61 [95% CI, 0.49–0.89]; P = 0.001). However, the risk of reported motor symptoms (HR, 0.54 [95% CI, 0.44–0.69]; P = 0.061) and/or autonomic symptoms (HR, 0.87 [95% CI, 0.62–1.22]; P = 0.229) was not significantly lower in the docetaxel group than in the nab-paclitaxel group.

Conclusion

In this cohort study of lung cancer patients, nab-paclitaxel was associated with more severe CIPN compared to docetaxel, regardless of patients’ clinical characteristics. Multivariate analysis identified taxane type, number of prior treatment cycles, treatment phase, and the use of pregabalin for intervention as independent factors associated with patient-reported CIPN. These findings may contribute to early intervention and therapeutic decision-making for CIPN during taxane-based treatment of lung cancer.

Schlagwörter

Stichwörter der Autor:innen

CIPNDOCETAXELNab-Paclitaxelpregabalinquestionnaire

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Resear…
  • Department of Oncology, The Central Hospital of Shaoyang, Shaoyang, China.

Zitieren

APA

Liu, Y., Li, Y., Li, X., Zhang, H., Liu, X., & Chen, P. (2026). Chemotherapy-induced peripheral neuropathy associated with docetaxel or nab-paclitaxel among patients with lung cancer: a prospective dual-center cohort study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1795686

Vancouver

Liu Y, Li Y, Li X, Zhang H, Liu X, Chen P. Chemotherapy-induced peripheral neuropathy associated with docetaxel or nab-paclitaxel among patients with lung cancer: a prospective dual-center cohort study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1795686

BibTeX
@article{Liu2026,
  author = {Liu, Yalan and Li, Yurong and Li, Xin and Zhang, Hui and Liu, Xinfu and Chen, Peng},
  title = {Chemotherapy-induced peripheral neuropathy associated with docetaxel or nab-paclitaxel among patients with lung cancer: a prospective dual-center cohort study},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1795686}
}
Kostenlos starten →